



Press release
2004-06-30

Anders Vahlne has been appointed managing director

As previously announced, Tripep AB is in the process of recruiting a new managing director. Johan Ihre, the current managing director, is finishing in his position today. Professor Anders Vahlne, a member of the board and one of the founders of Tripep, has been appointed new managing director pending the completion of the recruiting process.

For more information, please contact:

Anders Vahlne, CEO Head of Research
Phone +46 8-5858 1313, mobile +46 709-28 05 28
E-mail: anders.vahlne@labmed.ki.se
or
Rolf L Nordström, Chairman of the Board
mobil: 0044-777 613 7400
E-mail: rolf.l.nordstrom@btinternet.com

Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies:

- research and development of alfaHGA, a HIV-inhibiting drug,*
- preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS[®] technology platform.*
- producing vaccines against influenza, allergies and Alzheimer's disease through associated company VLP Biotech Inc.*

More details on Tripep's technologies are available at its Website: www.tripep.se